|Bid||64.66 x 1200|
|Ask||64.60 x 2900|
|Day's Range||63.78 - 64.73|
|52 Week Range||63.07 - 81.44|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||18.86|
|Earnings Date||Jul 27, 2023|
|Forward Dividend & Yield||2.28 (3.54%)|
|Ex-Dividend Date||Apr 06, 2023|
|1y Target Est||79.70|
Bristol-Myers' (BMY) top drugs, Revlimid and Eliquis, face challenges. It remains to be seen if the approval of new drugs can fuel growth and offset declines.
Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
NEW YORK, June 01, 2023--Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers' (BMY) NDA for repotrectinib for treating patients with NSCLC receives Priority Review from the FDA.
Its hefty yield isn't the only reason to consider buying this top pharma stock.
NEW YORK, May 31, 2023--Bristol Myers Squibb to Hold R&D Day on September 14
PRINCETON, N.J., May 30, 2023--BMS to Present Late-Breaking Data for Breyanzi in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 ICML
PRINCETON, N.J., May 30, 2023--US FDA Accepts for Priority Review BMS's Application for Repotrectinib
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
PRINCETON, N.J., May 26, 2023--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable...
PRINCETON, N.J., May 25, 2023--BMS's Breyanzi is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic....
PRINCETON, N.J., May 25, 2023--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment...
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
PRINCETON, N.J., May 25, 2023--Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
PRINCETON, N.J., May 22, 2023--Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
Let's consider the case of Bristol Myers Squibb (NYSE: BMY). The best pharmaceutical companies generally have deep pipelines that allow them to launch new products regularly and keep their revenue and earnings flowing in the right direction over the long run. This description applies to Bristol Myers Squibb.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Bristol-Myers Squibb (NYSE: BMY) is a top healthcare company with a rich history that goes back to the 1800s. Share prices of Bristol-Myers are down 11% over the past year, while the S&P 500 has been flat. A key reason investors haven't been too excited about Bristol-Myers' business is that the company's growth rate has typically been modest.
There has been no shortage of companies cutting dividends in the past year. If you're looking for some safety on the dividend front, consider Bristol Myers Squibb (NYSE: BMY), Verizon Communications (NYSE: VZ), and Coca-Cola (NYSE: KO).
In the last year, many Bristol-Myers Squibb Company ( NYSE:BMY ) insiders sold a substantial stake in the company which...